IM21 CAR-T cells

BIOLOGICAL3 trials

Sponsors

Peking Union Medical College Hospital, Beijing Immunochina Medical Science & Technology Co., Ltd.

Conditions

Multiple Myeloma

Early Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Beijing Immunochina Medical Science & Technology Co., Ltd.Multiple Myeloma

Start: 2021-05-06End: 2023-08-01Target: 10Updated: 2022-07-28

Phase 1

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

Peking Union Medical College HospitalMultiple Myeloma

Start: 2019-02-25End: 2021-12-20Target: 15Updated: 2020-09-30

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Beijing Immunochina Medical Science & Technology Co., Ltd.Multiple Myeloma

Start: 2020-09-03End: 2023-03-02Target: 10Updated: 2020-09-03

Related Papers

BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma

Journal for ImmunoTherapy of Cancer2024-09-017 citations

Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in &lt;3 Days Using the High-Performance Platform

Blood2022-11-153 citations

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion

Frontiers in Oncology2022-05-1611 citations